… of tocilizumab in the management of hospitalized COVID-19 patients. We searched
MEDLINE, CENTRAL and medRxiv for studies of tocilizumab in hospitalized COVID-19 patients. …

… of early tocilizumab treatment for hospitalized patients with … patients do not improve following
tocilizumab administration … that correct timing of tocilizumab administration is important. The …

… to SoC in hospitalized patients is associated with improved clinical recovery by day 28 and
shorter hospitalization. Our study differs from others in the selection of patients eligible for …

… and potential clinical benefit of the interleukin-6 inhibitor tocilizumab. We assessed the
efficacy of early tocilizumab treatment for hospitalized patients in a randomized phase II study. …

… Administration of tocilizumab was not associated with relevant … of administration of
tocilizumab in patients with COVID-19 pneumonia. A strategy involving tocilizumab administration …

… tocilizumab (19.7%) and placebo (19.4%) (difference, 0.3% [95% CI, –7.6 to 8.2]; nominal
P=0.94). Median time to hospital discharge was 8 days shorter with tocilizumab … tocilizumab …

… At 14 days, 24.6% of the patients in the tocilizumab group and 21.2% of the patients in the
… Patients who received tocilizumab had fewer serious infections than patients who received …

… patients who were hospitalized with severe Covid-19 pneumonia in a 2:1 ratio receive a single
intravenous infusion of tocilizumab … received a second dose of tocilizumab or placebo 8 to …

… of tocilizumab in adult patients admitted to hospital … Patients allocated to tocilizumab were
to receive tocilizumab as a single intravenous infusion over 60 min. The dose of tocilizumab …

… This study aimed to investigate the effectiveness of tocilizumab in COVID-19 patients. … effects
of adjunctive tocilizumab in hospitalized patients with COVID-19 and found that tocilizumab …